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An article in this issue of Chemistry & Biology (Hines et al., 2008) and a recent study in Nature (Groll et al.,
2008) establish three natural products as novel proteasome inhibitors. These inhibitors, discovered in an
unusual way, reveal a different mechanism of proteasome inhibition and suggest new therapeutic application
of its inhibitors.Targeted degradation of proteins by the
ubiquitin-proteasome pathway plays an
essential role in the regulation of protein
homeostasis and in the regulation of
essentially every function of the living
cells. The proteasome is a large,multisub-
unit, proteolytic complex that proces-
sively degrades ubiquitinylated proteins
into small peptides. Numerous inhibitors
of this degradation machine, discovered
in the past 15 years, serve as excellent
tools to determine proteasome involve-
ment in a cellular or physiological process
and to determine if a protein of interest is
degraded by the proteasomes (Kisselev
and Goldberg, 2001). Proteasome inhibi-
tors cause selective apoptosis of malig-
nant cells, and represent a new class of
antineoplastic agents (Adams, 2004).
One such inhibitor, bortezomib (VELCADE),
has been approved by the FDA for the
treatment of multiple myeloma and
mantle cell lymphoma. Three second-
generation proteasome inhibitors, carfil-
zomib (PR-171) (Demo et al., 2007),
salinosporamide A (NPI-0052) (Chauhan
et al., 2005), and CEP-18770 (Piva et al.,
2008), are in phase I and II clinical trials
(Figure 1).
Two recent papers, one inNature (Groll
et al., 2008), and one in this issue of
Chemistry & Biology (Hines et al., 2008)now report additional proteasome inhibi-
tors. If there are so many proteasome
inhibitors already available, why do these
compounds deserve special attention?
One of them inhibits the proteasome by
a mechanism not previously described
and the other suggests potential for addi-
tional therapeutic applications of these
compounds. In addition, these inhibitors
were discovered in an unusual way.
Groll et al. (2008) set out to investigate
the mechanisms of the Syringolin A (SylA,
Figures 1 and 2) virulence factor of the
plant pathogen Pseudomonas syringie.
Treatment of wheat and Arabidopsis
thaliana with this peptide derivative leads
to changes in gene expression profiles
that resemble changes occurring in yeast
and mammalian cells treated with protea-
some inhibitors (i.e., upregulation of tran-
scripts encoding proteasomal subunits
and heat shock proteins). This observa-
tion allowed Groll et al. to hypothesize
that this compound is a proteasome in-
hibitor. Indeed they found that it irrevers-
ibly inhibits all three types of proteasomal
proteolytic sites. In order to elucidate
the mode of inhibition, they solved the
structure of SylA complex with the yeast
20S proteasome. This structure revealed
a novel mode of inhibition whereby the
hydroxy group of proteasome’s catalyticChemistry & Biology 15, May 200threonine performs a Michael type 1,4-
addition to the vinyl ketone moiety in the
14-membered ring of the inhibitor (Fig-
ure 2). This mechanism resembles mech-
anisms of inhibition by another class of
proteasome inhibitors, peptidyl vinyl sul-
fones (Groll and Huber, 2004). They also
found that another microbal metabolite,
Glidobactin A (GlbA), inhibited the chymo-
trypsin- and the trypsin-like activities of
the proteasome and reacted with active
site threonines in a similar fashion. Both
SylA and GlbA blocked proliferation and
induced apoptosis of malignant cells, fur-
ther confirming that they are proteasome
inhibitors.
Hines et al. (2008) investigated the
mechanism of neurotropic activity of
marine fungal metabolite fellutamide B. It
was known that treatment of cultured
neurons and fibroblasts with this com-
pound induces nerve growth factor
(NGF) secretion, but the mechanism lead-
ing to this event had not been elucidated.
They noticed similarities in the structures
of this lipopetide aldehyde and peptide
aldehyde proteasome inhibitor MG132,
and tested whether it is a proteasome in-
hibitor. Indeed they found that fellutamide
B is a very potent inhibitor of the chymo-
trypsin-like sites and that it also inhibits
the trypsin-like and caspase-like sites,8 ª2008 Elsevier Ltd All rights reserved 419
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PreviewsFigure 1. Major Classes of Proteasome Inhibitors and Their Selected Representatives
Novel inhibitors described in this commentary are highlighted in yellow. ‘‘Founding members’’ of the family are highlighted in gray, except for novel macrocyclic
vinyl ketones, which are highlighted in yellow. Clinically used inhibitors are highlighted in blue. Pharmacophores (i.e., functional groups of the inhibitors that react
with proteasome’s catalytic threonines) are red. Cyclic peptides (TMC-95 and its derivatives) are the only inhibitors that do not interact directly with the active site
threonines.albeit at higher concentrations. It also
caused accumulation of ubiquitinylated
proteins in cultured cells. X-ray diffraction
revealed that it binds to all three catalytic
sites of the yeast 20S proteasome with
the formation of a hemiacetal bond. Inter-
estingly, the N-terminal aliphatic tail, which
distinguished this compound from other
peptide aldehydes reported to date,
adopts different conformations at different
active sites.
Two other proteasome inhibitors, MG
132 and the peptide epoxyketone epoxo-
micin, also upregulated NGF secretion,
confirming that fellutamide B-induced
NGF production is a consequence of pro-
teasome inhibition. It should be noted that
another natural product proteasome in-
hibitor, lacatacystin, was originally identi-420 Chemistry & Biology 15, May 2008 ª200fied as a compound that promotes neurite
outgrowth, and was later shown to be
a proteasome inhibitor (see Kisselev and
Goldberg, 2001, for review). Consistent
with this earlier observation, conditioned
media from epoxomicin and fellutamide
B treated cells caused neurite outgrowth
in undifferentiated PC12 cells. Secretion
of NGF was observed at the same con-
centration of fellutamide B as were other
well-documented effects of proteasome
inhibition (e.g., accumulation of ubiqui-
tinylated proteins, cell cycle arrest, and
cytotoxicity). At the same time, NGF was
not produced in response to other cyto-
toxic treatments, further strengthening
the conclusion that NGF production is
indeed the consequence of proteasome
inhibition. The authors then demonstratedFigure 2. Simplified Mechanism of Syringolin A Reaction with Proteasome Active Site
Threonines
Proteasome atoms are blue; inhibitor is black except for pharmacophore, which is red. Newly formed
bonds are purple.8 Elsevier Ltd All rights reservedthat this effect is a transcriptional re-
sponse and identified promoter regions
in the NGF gene that are responsible for
this response. This suggests that protea-
some inhibitors exert their neurotropic
effect by stabilizing a short-lived yet-to-
be-identified transcriptional factor that
regulates NGF gene expression.
In medical neurology there is an urgent
need for drugs to treat neuronal injury
caused by stroke, ischemia, and neurode-
generative diseases. One possibility is to
develop compounds that stimulate NGF
production. Can proteasome inhibitors be
used for these purposes? Given the overall
cytotoxicity of proteasome inhibitors and
high sensitivity of neuronal tissue to accu-
mulation of misfolded proteins, their appli-
cation for the treatment of chronic neuro-
degenerative diseases appears unlikely at
the moment. However, in situations where
a single short treatment is sufficient to pre-
vent neuronal injury, threrapeutic applica-
tions of proteasome inhibitors are certainly
possible. Specifically, proteasome inhibi-
tors are effective in prevention of reper-
fusion injury in animal models of cerebral
ischemia (Phillips et al., 2000). The expla-
nation for this effect is that this type of
Chemistry & Biology
Previewsbrain injury is caused by the development
of inflammation at the site of infarction.
Proteasome inhibitors block inflammation
bypreventing proteasome-dependent ac-
tivation of transcription factor NF-kB. The
study from the Crews group demonstrat-
ing neurotropic properties of proteasome
inhibitors (Hines et al., 2008) suggests
that an increase in NGF production can
also contribute to this effect. This should
stimulate the interest in continuation of
clinical testing of proteasome inhibitors
in stroke patients.
Finally, we would like to draw the
readers’ attention to the fact that all the
inhibitors discussed in these articles are
natural products, as are the well-known
proteasome inhibitors lactacystin, epoxo-
micin, and salinosporamide A, and the
less famous eponemycin, tyropeptin A
(Momose et al., 2005), and TMC-95. If pro-
teasome inhibitors are classified based on
chemical mechanisms, by which they in-
hibit the proteasome, sevenmajor classes
can be distinguished (Figure 1). Classes
represented by natural products outnum-
ber thosedevelopedbyorganic synthesis.Computational De
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The de novo design of enzymes with
lecular biology. Sophisticated comp
ing and rapidly evolving field (Ro¨thl
Natural evolutionhasyieldedenzymeswith
well-defined active sites in which virtually
all metabolic reactions are catalyzed with
high efficiency and specificity. It has been
a major goal of biochemistry for the past
century to understand the chemical and
molecular principles of these extremely
precise and exquisitemolecularmachines.
Recently, technical advances in molecular
biology have led to a renaissance in enzy-
mology by enabling researchers to modify
at will the activities and stabilities of manyIndeed, four of these classes (b-lactones,
peptide epoxyketones, cyclic peptides,
and macrocyclic peptide vinyl ketones)
were discovered as natural products. Nat-
ural products are represented in the fifth
class, peptide aldehydes, although these
compounds (e.g., MG132) were initially
developed by chemical synthesis. Only
two classes of inhibitor (peptide boro-
nates, e.g., bortezomib, and peptide vinyl
sulfones) do not yet have natural products
among them. Clearly, micro-organisms
learned of the importance of the protea-
some to their hosts long before scientists
discovered this fascinating particle. We
predict that this trend of discovery of pro-
teasome inhibitors among natural prod-
ucts will continue, and hold hope that
some of new inhibitors will open novel
therapeutic applications for these com-
pounds as the study by the Crews group
suggests.
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‘‘directed evolution.’’ In this two-step ap-
proach random mutagenesis is used to
create large enzyme repertoires, from
which optimized variants are then isolated
using either selection or screening tech-
niques (Bloom et al., 2005). In contrast
to directed evolution, the alternative ap-
proach of ‘‘rational’’ enzyme design re-
quires a detailed knowledge of a specific
enzyme structure and catalytic mecha-
nism (Woycechowsky et al., 2007). Al-
though occasionally successful, rational
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